News & Updates | Mogrify | Reprogramminng Health

FEATURED

CONTENT

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc., a leader in regenerative medicine, today announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.

Find out more

Latest

NEWS

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Mark Cavanagh2022-07-05T07:05:50+00:005th July 2022|

Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor

Mark Cavanagh2022-05-09T10:41:16+00:002nd November 2021|

Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer

Mark Cavanagh2022-05-09T10:41:26+00:005th October 2021|

Mogrify completes Series A financing totaling $33 million USD

Mark Cavanagh2022-05-09T10:41:36+00:004th May 2021|

Mogrify wins Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at CambridgeshireLive Business Excellence Awards 2020

Mark Cavanagh2022-05-09T10:42:08+00:0026th March 2021|

Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology

Mark Cavanagh2022-05-09T10:42:14+00:0011th January 2021|

Load More Posts

Latest

Resources

VIEW ALL RESOURCES

VIEW ALL MEDIA FEATURES

VIEW ALL EVENTS

Follow Us On

Social Media

Mogrify ·
@Mogrify_UK

Last month it was a pleasure to welcome @Julian_Gough, @OwenRackham and Jose Polo for Founders Week here at Mogrify. Discussing breakthroughs and new concepts in #bioinformatics and #cell reprogramming, as well as the cutting-edge science being conducted in their labs. https://t.co/E2iYjNmwVv

View on Twitter

2

10

Mogrify ·
@Mogrify_UK

Louise Modis, Mogrify CSO, joins @Labiotech_eu's Beyond Biotech #podcast to talk direct #cellularreprogramming, its role in the development of novel #invivoreprogramming therapies, and its application in our latest #collaboration with Astellas Pharma.

https://t.co/hzipwuCITu

View on Twitter

0

3

Mogrify ·
@Mogrify_UK

We are pleased to announce our #collaboration with @AstellasUS to conduct #research on #invivo #regenerativemedicine approaches to address sensorineural #hearingloss by generating new cochlear hair cells. Read more: https://t.co/NSx4hk0R2M #otology https://t.co/lIBSA015WE

View on Twitter

4

10

FEATURED

CONTENT

Latest

NEWS

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor

Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer

Mogrify completes Series A financing totaling $33 million USD

Mogrify wins Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at CambridgeshireLive Business Excellence Awards 2020

Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology

Latest

Resources

Follow Us On

Social Media

Subscribe to our

Newsletter

OUR INVESTORS

Newsletter

Quick Links

Quick Links

Get in touch